Trends in antifungal susceptibility of Candida species--one year observation

Insights

Opportunistic fungal infections are rising in immunocompromised patients. This study found Candida glabrata and Candida albicans were common causes of invasive candidiasis, with varying antifungal susceptibility.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Clinical Microbiology

Background:

  • Opportunistic fungal infections, particularly invasive candidiasis, have increased, especially in immunocompromised individuals.
  • The Candida genus is a significant cause of invasive fungal infections worldwide.
  • Understanding the prevalence and antifungal susceptibility patterns of yeast-like fungi is crucial for effective treatment.

Purpose of the Study:

  • To determine the prevalence of yeast-like fungi causing invasive candidiasis.
  • To assess the susceptibility of these fungal isolates to key antifungal agents.

Main Methods:

  • Culturing of 160 yeast-like fungal strains from diverse clinical samples (respiratory, blood, peritoneal fluid, etc.).
  • Quantitative E-test method employed for antifungal susceptibility testing.
  • Identification of predominant Candida species: C. glabrata, C. albicans, C. krusei, and C. tropicalis.

Main Results:

  • Candida genus was the primary etiological agent of invasive candidiasis.
  • Candida glabrata (71/160) and Candida albicans (34/160) were the most prevalent species.
  • All strains showed the highest resistance to itraconazole. C. glabrata exhibited 100% susceptibility to amphotericin B and caspofungin but was least susceptible to itraconazole, posaconazole, and voriconazole. C. albicans was most susceptible to all tested antifungals.

Conclusions:

  • Candida species, particularly C. glabrata and C. albicans, are major contributors to invasive candidiasis.
  • Antifungal susceptibility varies significantly among Candida species, with notable resistance to itraconazole.
  • C. glabrata demonstrates high susceptibility to amphotericin B and caspofungin, while C. albicans remains broadly susceptible to tested agents, guiding therapeutic strategies.